Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15633893 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL20154786 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL11843358 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9098838 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL7364954 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9097633 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9096777 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9099300 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL7526762 | 0.98 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL16330120 | 0.94 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310486-A1 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | E-THERAPEUTICS PLC (GB) | 2023-10-05 | — | — | US | disclosed |
| EP-0323441-B1 | 5-Fluorouracil derivatives | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0436902-B1 | 5-Fluorouracil derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-06-28 | — | — | EP | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180897-B1 | 5-FLUOROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-08-07 | — | — | EP | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-3976660-A | Pyrrolidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310486-A1 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | DCLRE1B, POLRMT, POLI | ALDH1A1 1107/4885MAPK1 4669/4885L3MBTL1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.